Evidence map›Paper›PMID 22695895›Full record

ArticleDer Internist2012

[Pharmacotherapy in patients suffering from chronic kidney disease].

J T Kielstein, F Keller

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Der Internist, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

J T KielsteinKlinik für Nieren- und Hochdruckerkrankungen, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland. kielstein@yahoo.com
F Keller
Medizinische Hochschule Hannover · DEUniversität Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The number of patients suffering from chronic kidney disease (CKD) is increasing worldwide and exceeds 15% of the entire population in industrialized countries. Half of the patients aged 70 + years suffer from CKD. The most prevalent underlying diseases leading to CKD are diabetes and hypertension. CKD per se increases the risk of cardiovascular events, cancer, and infections; hence, adequate and intensified pharmacotherapy is of utmost importance in this patient population. About 60% of all regularly used drugs are excreted by the kidney. For those, dose adjustment is of utter importance to avoid untoward effects and serious complications. The first important step for dose adjustment is the accurate estimation of renal function, i.e., glomerular filtration rate (GFR). Renal function cannot be assessed by serum creatinine alone as it only rises after a substantial (> 50%) loss of glomerular function and depends on many factors, e.g., age, gender, weight, and race. GFR can easily be estimated using formulas, e.g., the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.

Indexed as

HumansKidney Failure, ChronicKidney Function Tests

Identifiers

PMID22695895
OpenAlexW2120655250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.